We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info

Confirm

Discover Grünenthal

6/11/2013

Aachen (Germany) / Bogota (Colombia), November 6th 2013. The Grünenthal Group has signed an agreement with the Colombian pharmaceutical company BIOGEN® LABORATORIOS to take over one of its product portfolios including the corresponding trademarks. BIOGEN® LABORATORIOS has been operating in the market for more than thirty years.

The product portfolio comprises of 30 drugs (branded generics) that are all well-known and established in the Colombian market; some of them holding market leading positions in their respective segments.

In addition to pharmaceuticals for the treatment of pain, Grünenthal is taking over antiviral and anti-inflammatory drugs and medicines in the field of respiratory diseases and gynecology.

Amongst others the portfolio comprises the market leading antiviral drug Virex®, as well as further well-known and successful products such as Acibiogel®, Valcyclor®, Stopen® and Pilogan®. Currently, these products are predominantly marketed in Colombia.

The branded generics market is of significant value in Colombia and is growing above market average. With this take over, Grünenthal is further strengthening its Colombian subsidiary and expanding its portfolio by including products with high brand awareness and quality. Grünenthal will further drive the commercialization of the portfolio including targeted investments.

“Due to its overall market performance and growth expectations, Latin America plays a key role for Grünenthal in the realization of its corporate strategy. In September this year we have signed agreements for the potential acquisition of the Chilean company Empresas Andrómaco. Today’s transaction underlines that we are further investing and looking into investment opportunities in the region”, explained Prof. Eric Paul Pâques, Chairman of the Corporate Executive Board.

Oscar Ferenczi, Executive Vice President Grünenthal Latin America added: “The integration of these well-known brands into our portfolio supplements our current offer in key areas and strengthens our market position. We are convinced that the extended product portfolio will allow us to increasingly participate in the growth of this important Latin American market.”

Kurmann Partners advises Grünenthal within this transaction.


About Grünenthal

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation.

Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 26 percent of revenues in 2012. Grünenthal’s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.

Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries. Today, approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of €973 mn.


More information:
www.grunenthal.com.
 

Frank Schönrock

Vice President Public Engagement

Grünenthal GmbH


Aachen

E-Mail Frank.Schoenrock@grunenthal.com

Phone +49 241 569-1568